Latest news with #Cellino
Hindustan Times
12 hours ago
- Business
- Hindustan Times
Sampdoria's relegation lifeline confirmed with Salernitana play-off
Sampdoria will have a chance to avoid their first ever relegation to Italy's third division after a play-off with Salernitana was confirmed by Serie B. The former Italian champions fell to a historic low last month when a goalless draw at Juve Stabia on the final day of the regular season led to an 18th-placed finish in the 20-team division. The bottom three in Serie B are directly relegated to the third tier, while the teams in 16th and 17th place face off in a two-legged play-off. But Brescia dropped down to 18th after being deducted eight points for accounting and administrative infractions, four of which were applied to this past season and the remaining points to their next league campaign. Brescia did not appeal the ruling and are set to go out of existence after 114 years following owner Massimo Cellino's decision not to honour a debt of three million euros . Cellino had until Friday to pay part of Brescia's eight million euros in tax arrears and other overdue tax, and failure to do so has resulted in the club losing the right to take part in the Italian league system. That has given Sampdoria a lifeline, with a showdown with Salernitana deciding the final team to be relegated to Serie C alongside Brescia, Cittadella and Cosenza. One of seven Italian clubs who have played all their football in the top two divisions, Sampdoria will host Salernitana on Sunday, with the second leg in Salerno in southern Italy the following Friday. Sampdoria were relegated to Serie B in 2023 and close to going bust before being saved by current president Matteo Manfredi and former Leeds United owner Andrea Radrizzani, who has since exited the club. The club's majority shareholder is Singaporean businessman Joseph Tey. Club icons Alberico Evani and Attilio Lombardo were hired as coaches in April in an attempt to save Sampdoria from the drop after significant transfer market activity both last summer and in January. Evani is Sampdoria's fourth head coach of the season after Andrea Pirlo, Andrea Sottil and Leonardo Semplice. td/pi
Local Italy
3 days ago
- Business
- Local Italy
Historic Italian football club Brescia goes bankrupt
Italian businessman Massimo Cellino has owned the Lombardy club since 2017. Cellino was previously the owner of English side Leeds, where he was known for his managerial swinging door policy and his problems with the courts. The 68-year-old had until Friday to pay part of €8 million in tax arrears. Brescia's failure to pay the sum has resulted in the club losing the right to take part in the Italian league system. The club were deducted four points by the tribunal of the Italian football federation (FIGC) for their financial woes. As a result of the sanction, Brescia, which finished the Serie B season in 15th place with 43 points, dropped to 18th place with 39 points, resulting in relegation to the third-tier Serie C. Brescia spent 23 seasons in Serie A, with their best performance being an eighth-place finish in the 2000-2001 season. Famous past players of the club include Italian internationals Roberto Baggio, Alessandro Altobelli, Andrea Pirlo and Luca Toni, as well as current Manchester City boss Pep Guardiola, who played there between 2001 and 2003.
Yahoo
19-05-2025
- Business
- Yahoo
Cellino's iPSC Manufacturing Technology Receives FDA Advanced Manufacturing Technology (AMT) Designation
AMT Designation Positions Cellino to Accelerate the Development of Scalable, Personalized Regenerative Medicines CAMBRIDGE, Mass., May 19, 2025--(BUSINESS WIRE)--Cellino, a leader in advanced biomanufacturing, today announced that its optical biomanufacturing technology for generating induced pluripotent stem cells (iPSCs) has received the FDA's Advanced Manufacturing Technology (AMT) designation from the Center for Biologics Evaluation and Research (CBER). This prestigious designation highlights the transformative potential of Cellino's automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies. The FDA encourages the adoption of advanced manufacturing technologies (AMTs) that improve manufacturing reliability, product quality, and production scale. The AMT designation accelerates timelines for therapies manufactured using Cellino's optical biomanufacturing technology, offering higher priority within the FDA, along with earlier and more frequent interactions during Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) processes for a faster path to market. "We are honored to receive the AMT designation for our proprietary technology stack," said Nabiha Saklayen, Ph.D., CEO and Co-Founder of Cellino. "This recognition affirms our commitment to revolutionizing the production of patient-specific iPSCs, enabling faster and more consistent clinical and commercial-scale manufacturing. It's a pivotal moment in our mission to deliver personalized regenerative therapies that can scale globally, transforming healthcare for millions." Autologous iPSC manufacturing has long been one of the most complex challenges in biomanufacturing, involving labor-intensive processes like manual passaging and colony picking that only a limited number of experts worldwide can perform. These hurdles have slowed progress, preventing many therapeutic programs from advancing past early-phase clinical trials. Cellino's proprietary optical bioprocessing technology overcomes these challenges by introducing precision, reproducibility, and scalability, ensuring reliable, high-quality iPSC production for both clinical trials and commercial stages. "This AMT designation underscores the scientific rigor and transformative potential of our technology," said Marinna Madrid, Ph.D., Chief Product Officer and Co-Founder of Cellino. "Automated, optical manufacturing is key to ensuring patient access to regenerative medicines. This milestone brings us closer to scaling therapies from Phase 1 through large-scale commercialization, aiming to address some of the world's most debilitating chronic degenerative diseases." Cellino intends to leverage the AMT designation to expedite the translation of personalized iPSC-derived therapies into clinical practice. With global chronic disease burdens rising and more than 100 million individuals in the U.S. alone who could potentially benefit from iPSC-derived therapies, Cellino's technology is poised to significantly expand patient access to next-generation living medicines. For more information on the FDA's Advanced Manufacturing Technologies Designation Program, visit the FDA AMT Guidance. About Cellino Cellino is a leader in advanced biomanufacturing technology, committed to making personalized cell, tissue, and organ replacements a reality for patients around the world. Learn more at and follow us on LinkedIn and X. View source version on Contacts Media Kimberly HaKKH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
19-05-2025
- Business
- Business Wire
Cellino's iPSC Manufacturing Technology Receives FDA Advanced Manufacturing Technology (AMT) Designation
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cellino, a leader in advanced biomanufacturing, today announced that its optical biomanufacturing technology for generating induced pluripotent stem cells (iPSCs) has received the FDA's Advanced Manufacturing Technology (AMT) designation from the Center for Biologics Evaluation and Research (CBER). This prestigious designation highlights the transformative potential of Cellino's automated technology for scaling up high-quality iPSCs to industrialize next-generation regenerative therapies. The FDA encourages the adoption of advanced manufacturing technologies (AMTs) that improve manufacturing reliability, product quality, and production scale. The AMT designation accelerates timelines for therapies manufactured using Cellino's optical biomanufacturing technology, offering higher priority within the FDA, along with earlier and more frequent interactions during Investigational New Drug (IND), New Drug Application (NDA), and Biologics License Application (BLA) processes for a faster path to market. 'We are honored to receive the AMT designation for our proprietary technology stack,' said Nabiha Saklayen, Ph.D., CEO and Co-Founder of Cellino. 'This recognition affirms our commitment to revolutionizing the production of patient-specific iPSCs, enabling faster and more consistent clinical and commercial-scale manufacturing. It's a pivotal moment in our mission to deliver personalized regenerative therapies that can scale globally, transforming healthcare for millions.' Autologous iPSC manufacturing has long been one of the most complex challenges in biomanufacturing, involving labor-intensive processes like manual passaging and colony picking that only a limited number of experts worldwide can perform. These hurdles have slowed progress, preventing many therapeutic programs from advancing past early-phase clinical trials. Cellino's proprietary optical bioprocessing technology overcomes these challenges by introducing precision, reproducibility, and scalability, ensuring reliable, high-quality iPSC production for both clinical trials and commercial stages. 'This AMT designation underscores the scientific rigor and transformative potential of our technology,' said Marinna Madrid, Ph.D., Chief Product Officer and Co-Founder of Cellino. 'Automated, optical manufacturing is key to ensuring patient access to regenerative medicines. This milestone brings us closer to scaling therapies from Phase 1 through large-scale commercialization, aiming to address some of the world's most debilitating chronic degenerative diseases.' Cellino intends to leverage the AMT designation to expedite the translation of personalized iPSC-derived therapies into clinical practice. With global chronic disease burdens rising and more than 100 million individuals in the U.S. alone who could potentially benefit from iPSC-derived therapies, Cellino's technology is poised to significantly expand patient access to next-generation living medicines. For more information on the FDA's Advanced Manufacturing Technologies Designation Program, visit the FDA AMT Guidance. About Cellino Cellino is a leader in advanced biomanufacturing technology, committed to making personalized cell, tissue, and organ replacements a reality for patients around the world. Learn more at and follow us on LinkedIn and X.
